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Human Retinal Gene Therapy for Leber Congential Amaurosis Shows
Advancing Retinal Degeneration Despite Enduring Visual Improvement
Abstract
Leber congenital amaurosis (LCA) associated with retinal pigment epithelium-specific protein 65 kDa
(RPE65) mutations is a severe hereditary blindness resulting from both dysfunction and degeneration of
photoreceptors. Clinical trials with gene augmentation therapy have shown partial reversal of the dysfunction,
but the effects on the degeneration are not known. We evaluated the consequences of gene therapy on retinal
degeneration in patients with RPE65-LCA and its canine model. In untreated RPE65-LCA patients, there was
dysfunction and degeneration of photoreceptors, even at the earliest ages. Examined serially over years, the
outer photoreceptor nuclear layer showed progressive thinning. Treated RPE65-LCA showed substantial
visual improvement in the short term and no detectable decline from this new level over the long term.
However, retinal degeneration continued to progress unabated. In RPE65-mutant dogs, the first one-quarter
of their lifespan showed only dysfunction, and there was normal outer photoreceptor nuclear layer thickness
retina-wide. Dogs treated during the earlier dysfunction-only stage showed improved visual function and
dramatic protection of treated photoreceptors from degeneration when measured 5–11 y later. Dogs treated
later during the combined dysfunction and degeneration stage also showed visual function improvement, but
photoreceptor loss continued unabated, the same as in human RPE65-LCA. The results suggest that, in
RPE65 disease treatment, protection from visual function deterioration cannot be assumed to imply
protection from degeneration. The effects of gene augmentation therapy are complex and suggest a need for a
combinatorial strategy in RPE65-LCA to not only improve function in the short term but also slow retinal
degeneration in the long term.
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Leber congenital amaurosis (LCA) associated with retinal pigment
epithelium-speciﬁc protein 65 kDa (RPE65) mutations is a severe
hereditary blindness resulting from both dysfunction and degener-
ation of photoreceptors. Clinical trials with gene augmentation
therapy have shown partial reversal of the dysfunction, but the
effects on the degeneration are not known. We evaluated the con-
sequences of gene therapy on retinal degeneration in patients with
RPE65-LCA and its canine model. In untreated RPE65-LCA patients,
there was dysfunction and degeneration of photoreceptors, even
at the earliest ages. Examined serially over years, the outer photo-
receptor nuclear layer showed progressive thinning. Treated RPE65-
LCA showed substantial visual improvement in the short term and
no detectable decline from this new level over the long term. How-
ever, retinal degeneration continued to progress unabated. In RPE65-
mutant dogs, the ﬁrst one-quarter of their lifespan showed only
dysfunction, and there was normal outer photoreceptor nuclear
layer thickness retina-wide. Dogs treated during the earlier dysfunc-
tion-only stage showed improved visual function and dramatic
protection of treated photoreceptors from degeneration when
measured 5–11 y later. Dogs treated later during the combined dys-
function and degeneration stage also showed visual function im-
provement, but photoreceptor loss continued unabated, the same
as in human RPE65-LCA. The results suggest that, in RPE65 disease
treatment, protection from visual function deterioration cannot be
assumed to imply protection from degeneration. The effects of gene
augmentation therapy are complex and suggest a need for a combi-
natorial strategy in RPE65-LCA to not only improve function in the
short term but also slow retinal degeneration in the long term.
neurodegeneration | outer nuclear layer | retinal structure
Hereditary blindness can be caused by genetic defects in retinalpigment epithelium (RPE) cells, where a continuous supply
of 11-cis-retinal chromophore is produced by the visual cycle, or
in photoreceptors, where light photons captured by chromo-
phore molecules signal vision (1). One of the key components of
the visual cycle is the retinoid isomerase encoded by the RPE-
speciﬁc protein 65 kDa (RPE65) gene (2). Mutations in RPE65
cause Leber congenital amaurosis (LCA), a severe childhood
blindness (3). RPE65-associated LCA (RPE65-LCA) is a com-
plex disease in which vision loss results from two pathological
mechanisms—dysfunction and degeneration of photoreceptors
(3–6). RPE65-LCA has been proclaimed to be the ﬁrst suc-
cessfully treated inherited retinopathy using gene augmentation
therapy (7–10), and the treatment has resulted in substantial
improvement in vision that endures at least 3 y (11).
Whereas we showed that gene therapy corrects the biochemical
blockade leading to visual dysfunction and converts RPE65-LCA
from a two-mechanism disease into a simple retinal degeneration
(9), it has not been determined if therapy also treats the retinal
degeneration component. It is hypothesized that correction of the
underlying cellular dysfunction in a human recessive retinal de-
generation will promote greater neuronal survival by slowing the
natural rate of photoreceptor loss. Gene therapy experiments that
have evaluated photoreceptor degeneration have been performed
mainly in mouse and dog models treated at young ages (12–18)
and have implied that at least a subset of photoreceptors could be
rescued from degeneration. However, accumulating evidence has
suggested that human RPE65-LCA, which can show degeneration
prenatally or within the ﬁrst years of life (19, 20), is better modeled
at the more advanced disease stages in older animals (3, 21).
We evaluated the visual function and retinal degeneration in
treated and untreated eyes of patients with RPE65-LCA and in the
dogmodel of this disease. Gene therapy resulted in remarkable and
lasting improvements in visual function, but serial measurements of
outer photoreceptor nuclear layer (ONL) thickness showed con-
tinuing progression of photoreceptor loss. Our human and canine
results are consistent with the hypothesis that the majority of
photoreceptors in the degenerative phase of RPE65 disease is
destined for progressive loss. Treatment of RPE65-LCA should
evolve into a two-pronged intervention that not only leads to visual
restoration in the short term but also, improved photoreceptor
survival in the long term.
Signiﬁcance
The ﬁrst retinal gene therapy in human blindness from RPE65
mutations has focused on safety and efﬁcacy, as deﬁned by
improved vision. The disease component not studied, however,
has been the fate of photoreceptors in this progressive retinal
degeneration. We show that gene therapy improves vision for
at least 3 y, but photoreceptor degeneration progresses un-
abated in humans. In the canine model, the same result occurs
when treatment is at the disease stage equivalent to humans.
The study shows the need for combinatorial therapy to im-
prove vision in the short term but also slow retinal de-
generation in the long term.
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Human RPE65-LCA: Natural History of Photoreceptor Degeneration.
Our cohort of RPE65-LCA patients (Tables S1 and S2), including
those patients as young as 3 y of age, had abnormal ONL thick-
ness at a majority of sampled retinal locations (Fig. S1), consis-
tent with previous reports of loss of photoreceptors detectable at
the earliest ages evaluated to date (6, 19, 20, 22–24). Untreated
RPE65-LCA eyes were examined longitudinally to measure the
rate of progression of this early-onset retinal degeneration. Pa-
tient 23 (P23) illustrates the spatiotemporal progression of reti-
nal degeneration (Fig. 1 A–D). Optical coherence tomography
(OCT) scans across a 15-mm extent along the vertical meridian
crossing the fovea (Fig. 1A) show the intraretinal backscattering
differences that delineate retinal sublaminae corresponding to
different cell layers (20). Quantitatively, the ONL thickness shows
changes at most retinal locations (Fig. 1 A and B). Thinning of the
ONL fraction (ONL thickness of the patient divided by mean
normal thickness at the same retinal location) at most extrafoveal
retinal locations showed log-linear progression (Fig. 1C), which is
consistent with a model wherein the photoreceptor degeneration
follows an exponential decay after a retinal locus-speciﬁc onset of
photoreceptor degeneration (25, 26). To a ﬁrst approximation,
kinetics of ONL loss followed similar exponential decay rates
irrespective of retinal location. This invariant exponential decay
was estimated from the median value of the population of slopes
calculated from each of the consecutive pairs of measurements.
The onset of progressive degeneration phase was estimated at
each retinal location by extrapolating along the median slope to
0 log ONL fraction, and all of the data was replotted to illustrate
how a single underlying natural history can predict disease pro-
gression across multiple retinal locations at different disease
stages (Fig. 1D).
Fifteen patients (ages 7–29 y at ﬁrst visit) (Table S1) were ex-
amined serially (over periods ranging from 1.2 to 6.7 y, average =
4.6 y) to understand better the inter- and intraretinal variation of
the natural history of retinal degeneration in RPE65-LCA (Fig.
1E). ONL thickness fraction from all retinal locations and all
patients showed a wide variation when plotted against chrono-
logical age (Fig. 1E). There was a weak negative correlation
with age both at inferior (slope = −0.015 log/y; r2 = 0.12) and
superior (slope =−0.016 log/y; r2 = 0.11) retinal loci (Fig. 1E). To
form a predictive natural history of disease applicable to RPE65-
LCA, we calculated the median of the exponential rates across all
patients, all retinal locations, and all consecutive pairs of meas-
ures (n = 426). On adjustment for the individual and locus-spe-
ciﬁc onset of the progressive degeneration phase, the underlying
natural history (Fig. 1F) was highly consistent (r2 = 0.91) with a
steeper slope (−0.04 log10/y) compared with the same data plot-
ted against chronological age.
Natural History of Visual Sensitivity in Human RPE65-LCA. Patients
with RPE65-LCA show a substantial loss of light sensitivity un-
explained by the amount of underlying photoreceptors (3, 6, 10,
22, 27). It is important to emphasize, however, that the patients do
not lose all visual function. Often, there is measurable remnant
vision that is mediated by rods, cones, or both (11, 22, 27). The
source of this remnant vision or its natural history is not un-
derstood in RPE65-LCA.We next asked the question: what would
be the expected change in sensitivity during the time span of
measured ONL thinning? For simple retinal degenerations, a
change in sensitivity should be proportional to the square of the
change in ONL thickness (6). For the median exponential de-
generation rate of −0.04 log/y, the corresponding change in sen-
sitivity would be −0.08 log/y (Fig. 1G, expected). Progression of
vision loss is expected to be similar to simple retinal degenerations,
although the absolute sensitivity is dissociated from ONL thick-
ness (6). To evaluate this hypothesis, we measured the change in
light sensitivity along the vertical meridian at the same retinal
locations and in the same patients as those patients included for
the study of ONL change over time (Table S1). Unexpectedly,
there was little detectable change measured in sensitivity. A re-
gression line ﬁt to the visual function data over a time horizon
extending to 6 y showed a slope of −0.02 log/y (Fig. 1G, observed;
−0.007 log/y if the regression line was forced to go through the
origin), which was more shallow than the slope expected from the
underlying photoreceptor degeneration.
Gene Therapy Does Not Slow the Progressive Retinal Degeneration in
RPE65-LCA. To determine the consequences of subretinal gene
therapy on retinal degeneration, three analyses were performed:
(i) intraocular comparisons were made of ONL fractions between
treated and untreated retinal regions of the same eye; (ii) inter-
ocular comparisons were made of ONL fractions between study
eyes and contralateral control eyes; and (iii) the progression of the
ONL fraction in study eyes was compared with the expected nat-
ural history ofRPE65-LCA.All analyses were performed along the
vertical meridian. Treated regions in study eyes received the sub-
retinal therapeutic vector and showed a signiﬁcant improvement
in visual function during the 90-d period after surgery. Control
regions in study eyes did not receive the subretinal therapeutic
vector and did not show change in visual function parameters
during the same time period.
The ﬁrst analysis is illustrated by the intraocular comparison
data from the study eyes of P7 and P2; control [Fig. 2A, red bars
(inferior retina)] and treated [Fig. 2A, green bars (superior retina)]
regions are shown. For the control region in P7, the mean ONL
fraction was 0.73 at baseline and reduced to 0.45 at 3 y later. For
the treated region, the ONL fractions were 0.52 and 0.32 at
baseline and 3 y later, respectively. Results in the study eye of P2
showed a similar reduction of ONL fraction at 3 y compared with
baseline for both types of regions (from 0.57 to 0.38 at the control
region and from 0.49 to 0.35 at the treated region). When ONL
fractions from study eyes were compared, there was no signiﬁcant
difference (P = 0.91, Mann–Whitney rank sum) at baseline be-
tween regions (treated quartiles = 0.22, 0.40, 0.57; untreated
quartiles = 0.24, 0.29, 0.57). At the last available visit after the
treatment (Table S2), retinal regions showed thinner ONL com-
pared with baseline, but there remained no signiﬁcant difference
(P = 0.66) between treated and untreated regions (treated quar-
tiles = 0.17, 0.25, 0.36; untreated quartiles = 0.16, 0.26, 0.42).
In the second analysis, ONL fractions from treated study eyes
and untreated control eyes (Tables S1 and S2) were compared.
There was no signiﬁcant difference (P=0.70,Mann–Whitney rank
sum) at baseline between eyes (study eye quartiles = 0.22, 0.40,
0.57; control eye quartiles = 0.22, 0.33, 0.51) when considering
matched retinal regions (n= 36 regions in nine patients) that were
later found to have been successfully treated in study eyes. At the
last available visit, retinal regions showed thinner ONL compared
with baseline, but there remained no signiﬁcant difference (P =
0.99) between the eyes (study eye quartiles = 0.17, 0.25, 0.36;
control eye quartiles = 0.16, 0.26, 0.44). Similarly, for untreated
regions in study eyes and their matched regions in control eyes (n=
37 regions in nine patients), there were no signiﬁcant differences
in ONL fraction at baseline (P= 0.79) or at the last visit (P= 0.52).
In the third analysis, data from study eyes were compared with
the expected model of the natural history of degeneration (Fig.
2B). For these analyses, the start of the degeneration phase was
estimated from the ONL thickness fraction measured at baseline,
and all posttreatment time points were then plotted with respect
to the baseline value. The great majority of 45 control regions (11
eyes) (Fig. 2B, Left) showed progressive thinning of the ONL that
was not substantially different from the natural history observed
in untreated eyes. There were rare locations that showed no
change or greater than expected deviation. For the 36 treated
regions, the results were similar (nine eyes) (Fig. 2B, Right); the
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great majority progressed along the expected natural history, with
rare regions showing no change or greater than expected de-
viation. When the ONL fraction deviations between the mea-
sured data and the natural history model were compared, there
were no statistically signiﬁcant differences between treated re-
gions in study eyes, control regions in study eyes, and all loci in
untreated eyes (P = 0.81, Kruskal–Wallis ANOVA on ranks). In
summary, all three analysis methods supported the conclusion
that gene therapy has not modiﬁed the natural history of pro-
gressive retinal degeneration in the RPE65-LCA patients.
Early Visual Improvements Persist Up to 3 y After Human Gene
Therapy. Visual sensitivity at the control regions of treated eyes
was not signiﬁcantly changed compared with baseline (Fig. 2C).
The regression line showed a nearly zero slope (0.02 log/y) instead
of a slope of −0.08 log/y expected based on the retinal degen-
eration rate estimated at the same retinal locations. In a subset
of patients, visual function data for up to 4.5 y (average = 2.1 y,
n = 6) before treatment were available (Fig. 2C, purple symbols)
and consistent with the stability observed posttreatment. These
results mirrored our observations in untreated control eyes (Fig.
1G). At the treated retinal locations, there were substantial im-
provements in visual sensitivity averaging 1.6 (range= 0.8–2.4) log
units better than baseline within a short (30–90 d) period (Fig.
2C). Long-term evaluation of the treated locations showed mostly
stability or additional improvement of the sensitivities (Fig. 2C,
regression slope 0.04 log/y), results that were in contrast to the
continuing degeneration measured at the same locations of the
same eyes (Fig. 2B).
Natural History of Photoreceptor Degeneration in RPE65-Mutant
Dogs. Next, we asked whether the posttreatment results of ad-
vancing retinal degeneration despite enduring visual improvement
were unique to human RPE65-LCA or also occurred in an animal
model of the disease. RPE65-mutant dogs are the only large ani-
mal model for RPE65-LCA and are known to show congenital
visual dysfunction followed later by retinal degeneration (5, 17,
28–32). First, we deﬁned the natural history of the canine disease.
The thickness of the ONL layer recorded with noninvasive cross-
sectional OCT retinal imaging was used to estimate the spatial
pattern of the onset and progression of the retinal degeneration.
Histological data in a limited number of dogs were also used in
the analyses. Normal dogs showed thicker ONL in the superior
(tapetal; nonpigmented RPE) retina compared with inferior
(nontapetal; pigmented RPE) retina (Fig. 3A). RPE65-mutant
dogs at 5 y of age could show nearly normal ONL thickness to-
pography (Fig. 3B). By 8 y of age, there was substantial thinning
of the ONL, with detectable photoreceptors remaining across the
central (visual streak) retina extending into the superior retina
(Fig. 3C).
Five locations in inferior, superior, and central retina were
chosen (squares in Fig. 3 A–C) to quantify the natural history of
ONL changes in RPE65-mutant dogs compared with normal dogs
(Table S3). At all ﬁve locations, normal eyes showed a small
amount of ONL thinning (−0.014 log/y) over the ﬁrst 8 y of dog
life (Fig. 3 D–F, gray circles and lines). In RPE65-mutant eyes, at
the two inferior retinal loci, ONL fraction measurements were
consistent with the onset of the photoreceptor degeneration oc-
curring near 4.9 y (Fig. 3D). At the two superior retinal loci, there
was a similar natural history, but disease onset was delayed to 5.3 y
(Fig. 3E). At the central retinal locus (nasal to the optic nerve on
or near the visual streak), most of the eyes showed normal or
near-normal ONL thickness. Limited data from a 10-y-old dog
Fig. 1. Natural history of disease in untreated human RPE65-LCA. (A) Cross-
sectional OCT retinal scans in P23 performed along the vertical meridian
(Inset) at ages 20 and 24 y. Vertical dashed lines delimit the 10 extrafoveal
regions quantiﬁed. ONL is highlighted in blue for visibility. F, fovea. (B) ONL
thickness of P23 as a function of eccentricity at ages 19, 20, 23, and 24 y
shows progressive thinning at most retinal locations. (C) Logarithm of the
ONL fraction against age supports an underlying exponential decay function
describing progression. (D) Data from C replotted after horizontal shifts
accounting for differences in the onset of degeneration at each retinal re-
gion. (E) ONL thickness in untreated RPE65-LCA eyes shows an extremely
wide spectrum of results with a weak tendency of thinning as a function of
chronological age. (F ) Data from E replotted after horizontal shifts ac-
counting for differences in age of onset. Results show a predictable natural
history underlying the progressive degeneration in most patients. Dashed
lines delimit the range of deviation (±2 SD) of the data from the model. (G)
Average visual sensitivities measured at the same retinal locations in the
same patients are stable over time and do not conform to the expected slope
(red) estimated from the ONL degeneration. Error bars are SE. Numbers of
eyes contributing to each data point are shown.














were consistent with the onset of photoreceptor degeneration
being delayed to as much as 7 or more y (Fig. 3F). In summary,
RPE65-mutant dogs displayed only the dysfunction component
of the RPE65 disease for an extended period ranging to at least
one-quarter of their lifespan. Onset of retinal degeneration in
RPE65-mutant dogs occurs relatively late at ages equivalent to
∼30 human y (33).
Gene Therapy in RPE65-Mutant Dogs Rescues Progressive Retinal
Degeneration only When Delivered Before the Onset of Retinal
Degeneration. Results from two dogs illustrate the long-term
success in preventing the photoreceptor loss when RPE65 gene
therapy is delivered before the onset of retinal degeneration (Fig.
4 A and B). Dog 23 (D23) received a subretinal injection in
the central and inferior nasal retina of the right eye at the age of
0.3 y. Electroretinogram (ERG) recordings for the ﬁrst 3 y after
treatment were markedly improved for rod and cone amplitudes
compared with untreated eyes (34, 35). ERGs at age 9.7 y re-
mained sizable, suggesting a durability of functional gains by rods
and cones for nearly a decade (Fig. S2). By OCT, ONL thickness
was undetectable outside the injected region, but there was
substantial ONL remaining within the treated region (Fig. 4A).
Quantitative results were consistent with nearly normal ONL
thickness within the treated region in infero-nasal and central
retina (Fig. 4 C and E, green diamonds), relatively retained ONL
in the supero-nasal retina (Fig. 4D, green diamond), and severe
retinal degeneration consistent with the natural history of disease
in untreated supero-temporal and infero-temporal retinal loca-
tions (Fig. 4 C and D, red diamonds). D25 received, at age 1.9 y,
a subretinal injection that extended from near the optic nerve
into superior retina. ERG recording nearly 5 y after the treat-
ment at 6.7 y showed signiﬁcant functional improvement (Fig.
S2). ONL thickness topography at age 6.7 y indicated that there
was a retained area corresponding to the treatment region (Fig.
4B). Quantitative results in the inferior untreated retina were
consistent with the natural history (Fig. 4C, red up triangles). In
the treated superior retina, however, ONL thickness in D25 was
within the normal range and substantially greater than expected
from the natural history of RPE65 disease (Fig. 4D, green up
triangles). The treated one-half of the central retinal region of
D25 had near-normal ONL thickness, which was expected from
the natural history. These results underscore the importance of
understanding spatiotemporal distribution of the disease to in-
terpret therapeutic effects (Fig. 4E).
ONL thickness mapping and quantitative measurements were
performed in three additional eyes (D24, D26, and D27) (Table
S3) injected subretinally in the superior retina at ages 1.8–2.4 y and
evaluated at ages 6.6–7.2 y (Fig. 4 C–E). All three eyes showed
signiﬁcant ERG improvements nearly 5 y after the treatment at
ages of ∼7 y (Fig. S2). ONL fraction in control regions outside of
the injection region was not different from the natural history of
RPE65 disease in dogs (Fig. 4 C and E, smaller red symbols). In
treated superior retinal regions, ONL fraction was normal or near
normal, showing substantial rescue compared with the natural
history of RPE65 disease (Fig. 4D, smaller green symbols).
The eyes of the ﬁve early-treated dogs were examined by his-
tology at the end of the study (Table S3). Histology results were
well-correlated with those results obtained with noninvasive OCT
imaging. The ﬁndings for D23, D25, and D26 are illustrated (Fig.
5 and Fig. S3). In general, photoreceptor morphology was normal
in the center of the treatment area, with an intact ONL and
preservation of inner retinal layers (Fig. 5B and Fig. S3 B and E).
Towards the margins of the treatment areas, the ONL gradually
thinned, and photoreceptors became shorter, broader, and
more disoriented (Fig. 5C and Fig. S3C). Outside the treatment
boundary, there was an abrupt loss of photoreceptors, with
prominent retinal gliosis and loss of layer organization (Fig. 5D).
RPE65 immunolabeling showed distinct cytoplasmic labeling within
the treatment areas (Fig. 5B1), but none outside (Fig. 5D1). It
appeared that RPE65 expression was most intense in the center of
the treatment area and less intense and uniform towards the edges.
Fig. 2. Photoreceptor degeneration in human RPE65-LCA eyes that have
had gene therapy. (A) Cross-sectional OCT scans in two patients, P7 and P2,
at baseline (BL) and 3 y after treatment. Green lines demarcate the region
superior to the fovea that received a subretinal injection and that visual
function measurements showed signiﬁcant improvements in sensitivity. Red
lines demarcate the untreated control retinal regions. ONL is highlighted in
blue for visibility. (Insets) Thickness of the ONL at BL and posttreatment time
points compared with mean normal (N) shows degeneration occurring at
most loci. (B) ONL measures in control (Left) and treated (Right) retinal
regions plotted on the natural history of RPE65-LCA disease deﬁned in Fig.1.
The progression in control and treated regions is, for the most part, in-
distinguishable from the natural history. (C) Visual sensitivities measured at
control (Left) and treated (Right) retinal locations in the same patients.
Control locations show stable sensitivities before and after surgery. Treated
locations show a dramatic improvement after the surgery that is retained
over time. Pretreatment measures are shown with purple symbols in B and C.
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Of interest, regardless of the expression of the RPE65 transgene in
the treated regions, there were no apparent changes in the size and
number of the vacuolated RPE inclusions that are characteristic of
the disease (35).
When gene therapy was performed in eyes of mutant dogs older
than 4.8 y (Table S3), an age when at least part of the retina shows
photoreceptor loss in most of the animals, visual function im-
proved within 1 mo (Fig. S2), but retinal structural results obtained
1 y later did not show a positive modiﬁcation of the natural history
of photoreceptor degeneration (Fig. 4 F–J). Illustrating these
results are D19 injected in the infero-temporal retina (Fig. 4F) and
D22 injected in the supero-nasal retina (Fig. 4G) at ages 5.1 and
6.4 y, respectively. When imaged more than 1 y later, there was no
obvious retention of ONL thickness corresponding to the treated
regions. Quantitative results in dogs treated after 4.8 y of age (D16,
D17, D19, and D22) showed ONL fraction consistent with the
expected natural history of disease both in treated (Fig. 4 H–J,
green symbols) and untreated (Fig. 4 H–J, red symbols) locations.
These results are consistent with the hypothesis that gene therapy
after the onset of retinal degeneration did not substantially modify
the natural history of disease in the mutant dog.
Discussion
Gene augmentation therapy for human RPE65-LCA, as per-
formed in four independent clinical trials, has resulted in sub-
stantially improved visual function within days to weeks after
treatment (7–10), and the functional gain has been durable for
as long as 3 y (11, 36) (Fig. 2C). These positive results bode well
for the ability of gene therapy to partially ameliorate the severe
and lifelong visual impairment experienced in RPE65-LCA. It is
important to remember, however, that this vision loss is caused
by a combination of a biochemical chromophore deﬁciency and
a progressive degeneration of cone and rod photoreceptor cells
(3). Restoration of RPE65 expression through gene therapy is
thought to treat the chromophore deﬁciency, but it has also been
assumed that treating the primary biochemical deﬁciency would
slow or arrest the (presumed) secondary degeneration. Here, we
test this assumption by determining if there is progression of
retinal degeneration in patients with RPE65-LCA treated with
gene therapy. We ﬁnd that gene therapy causes substantial and
durable vision improvement but does not slow the natural history
of photoreceptor degeneration. Our ﬁndings have similarities to
treatments applied to the CNS that lessen symptoms but do not
slow the neurodegeneration (37, 38). The practical implication
Fig. 3. Natural history of retinal degeneration in Rpe65-mutant dogs shows regional effects. (A–C) Photoreceptor (ONL) thickness topography in a normal
dog compared with two Rpe65-mutant dogs at different ages. ONL thickness topography is mapped to a pseudocolor scale. I, inferior; N, nasal; S, superior
retina; T, temporal. Reconstituted OCT scans along a superior–inferior meridian (line) are shown in Lower with the ONL layer highlighted in blue. Retinal
distances are speciﬁed relative to the point closest to the optic nerve. Note that the OCTs shown are reconstituted from ultra-wide angle maps covering more
than 80° × 80° (∼24 × 24 mm) sampled at 1°. (D–F) ONL thickness quantiﬁed as a function of age at ﬁve retinal locations (shown as squares in A–C): two
inferior loci (D), two superior loci (E), and a nasal central visual streak locus (F). Gray symbols represent normal animals; black symbols represent RPE65-mutant
dogs. Gray lines approximate the expected range of normal results. Hashed regions within gray lines show the dysfunction-only stage, and hashed regions
within black lines show the dysfunction and degeneration stage of RPE65 disease. Insets are 60° × 60° and show the ﬁve retinal locations sampled with OCT
and two locations sampled with histology. Overlapping symbols have been moved horizontally to aid in their visibility.














of our results is that human treatments of RPE65-LCA should
address the need to slow or arrest the retinal degeneration that is
present and ongoing in these patients, no matter how young they
are when considered for enrollment in clinical trials to treat the
dysfunction component of their complex disease.
To determine success of any treatment intended to slow the rate
of retinal degeneration, an estimate should ﬁrst be made of the
rate of natural progression without treatment. For RPE65-LCA,
the momentum toward treatment in the clinic was so great after
proof-of-concept success in animals that there was no waiting for
natural history data to emerge. Treatment for a genetic retinal
disease, for the ﬁrst time in history, took priority, and early reports
of visual improvement seemed to validate that it was unnecessary to
establish a rate of retinal degeneration. Now, as plans are an-
nounced to extend these initial trials to treating very young patients,
both eyes, and greater retinal areas, we felt the need to revisit
ﬁrst principles. We made serial measurements of ONL thickness
in untreated eyes of RPE65-LCA patients and estimated the rate
of photoreceptor loss to be, on average, −0.04 log10/y (−9.6%/y)
under a delayed exponential model of disease (25, 39–41). This
progression rate is comparable with the rate estimated in a dif-
ferent retinal degeneration caused by MYO7A mutations using
similar methods and longitudinal data (26) and within the range
of progression rates estimated from visual function measures in
other retinal degenerative diseases (25, 40, 41).
How do our estimates of the rate of progression of retinal
degeneration in human patients compare with animal models of
RPE65-LCA? Rpe65−/− mice show an onset of degeneration near
3–4 mo (4, 42) and a degeneration rate averaging −0.22 log10/y
(21). Assuming an allometric relationship between rates of neuro-
degeneration and maximum lifespan (33), the Rpe65−/− mouse
disease is much slower than human disease (6, 19–24, 43–45),
with an onset that is equivalent to 9–12 human y and a rate that
corresponds to −0.006 log10/human y. RPE65-mutant dogs were
also known to have slow photoreceptor degeneration (5, 29, 30,
32), but the details of spatiotemporal progression were unknown.
Our results showed that the onset of degeneration ranges from
5 to 8 y depending on retinal location. By allometric scaling, this
range corresponds to 31–48 human y. The progression rate in
RPE65-mutant dogs averaged −0.33 log10/y, corresponding to
−0.05 log10/human y. Thus, both murine and canine models show
an extended period (up to 25% of their lifespan) with a retina-
wide dysfunction-only phase that does not seem to have an
equivalent in human RPE65-LCA at any age observed to date
(6, 19–24, 43–45). Human RPE65-LCA is best modeled in older
animals clearly displaying the dysfunction as well as degeneration
phases of RPE65 disease. During this combined phase, the rate
of progression in the canine model seems to be more similar to
the human disease compared with the rate observed in the mu-
rine model.
Preclinical experiments of gene augmentation therapy have
been mostly performed in young RPE65-mutant animals at a dis-
ease stage preceding the onset of photoreceptor degeneration,
and most investigations have focused on the restoration of visual
function and safety of the intervention (12, 13, 34, 35, 46–52).
Here, we evaluated the retinal degeneration in ﬁve younger dogs
treated during the dysfunction-only stage of disease by longitu-
dinally following them for 5–11 y after treatment. The results
showed unequivocal survival of the photoreceptors within the
treated region that would have otherwise degenerated. Non-
invasive OCT studies localized the region of preservation, and
histological studies showed intact ONL and preservation of inner
retinal layers. Our studies conﬁrm and extend previous studies
(14, 17, 35), and they support the hypothesis that, in RPE65-
mutant dogs, early treatment of the primary RPE defect prevents
the later onset of photoreceptor degeneration. Similar experi-
ments in mutant mice treated early with gene therapy have shown
survival of cone (12, 13, 15, 16) and rod photoreceptors (49).
Investigation of the mechanism(s) causing photoreceptor cell loss
(18, 53–56) has been mostly performed in untreated eyes to date.
Extension of such studies to eyes undergoing gene therapy (18)
would be important to clarify molecular underpinnings of the
observed modiﬁcation of natural history. Furthermore, the newly
discovered vitamin A isomerization pathway originating in Muller
Fig. 4. Gene therapy applied before and after the onset of retinal de-
generation in Rpe65-mutant dogs. (A and B) Photoreceptor (ONL) thickness
topography in two dogs (D23 and D25) treated before the onset of the
degeneration and evaluated ∼5–9 y later. There is much better retention of
ONL thickness within the treatment region (dashed lines) compared with
outside the treatment region. (C–E) ONL thickness quantiﬁed as a function
of age at ﬁve retinal locations in ﬁve dogs treated before the initiation of
degeneration. Red symbols correspond to retinal locations outside the
treatment region, and green symbols correspond to locations within the
treatment region. (F and G) ONL thickness topography in two dogs (D19 and
D22) treated after the onset of degeneration. There is no evidence for
thicker ONL within the treatment regions compared with outside the
treatment regions. (H–J) ONL thickness quantiﬁed as a function of age at
ﬁve retinal locations in treated eyes. Both untreated control (red symbols)
and treated (green symbols) regions are not substantially different com-
pared with the natural history of disease. Larger symbols in C–E correspond
to data shown in A and B, and larger symbols in H–J correspond to data
shown in F and G.
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cells and subserving cones (57) may be found to contribute to the
differences in (cone or rod) photoreceptor survival.
Our cohorts of RPE65-LCA patients who received gene ther-
apy (9, 11, 36) showed remarkable and lasting improvements in
visual function, but our serial measurements of ONL thickness
now show that photoreceptor loss has continued along a trajec-
tory no different from the expected natural history. In parallel
experiments that we performed in older RPE65-mutant dogs,
gene therapy applied after the onset of retinal degeneration did
not seem to increase photoreceptor survival. To explain both
ﬁndings, we postulate that there exists a critical limit in terms of
accumulating molecular changes that are detrimental to photo-
receptor survival under this condition of severe RPE65 dysfunc-
tion. There is evidence for molecular changes occurring in rod
and cone photoreceptors in the predegenerative phase of RPE65
disease (17, 18, 32, 54, 58), and a speciﬁc translocation of one of
the proapoptotic Bax isoforms from the cytosol to mitochondria
has been observed to correlate with the initiation of photore-
ceptor cell loss (54, 55). To date, there has been a paucity of
murine studies of gene therapy in older animals after the onset of
retina-wide rod degeneration (6, 59). Expansion of such studies is
required to better understand the molecular changes that are as-
sociated with inevitable loss of photoreceptors or successful pro-
tection from degeneration following gene augmentation therapy.
RPE65-mutant animals are not alone in requiring gene aug-
mentation therapies to be applied in a predegenerative phase.
Several murine models of primary photoreceptor diseases—such
as mice with Aipl1, Rpgrip1, Pde6b, Bbs4, and Cngb1 defects—
show improved photoreceptor survival when therapies were ap-
plied before or at the early stages of retinal degeneration (60–64).
To date, there has been only one demonstration of gene aug-
mentation therapy applied after the onset of retinal degeneration
that showed improved survival of photoreceptors (65). It remains
to be determined whether this difference in outcome of canine
retinitis pigmentosa GTPase regulator (RPGR) disease vs. other
photoreceptor or RPE diseases in mouse models is because of
species differences in the pathophysiology of disease or other
treatment variables.
Untreated eyes of RPE65-LCA patients showed abnormal but
stable visual function at the same retinal locations that were
showing progressive loss of photoreceptors over the same obser-
vation period. Similarly, in treated eyes, the improved visual
function in the short term did not diminish in the longer term with
the progression of degeneration. These pairs of seemingly para-
doxical ﬁndings may be explained by a number of hypotheses alone
or combined. Two of these hypotheses involve the source of the
remnant function driven by a chromophore, the identity, source,
and concentration of which are currently unknown. A ﬁrst hy-
pothesis proposes that in RPE65-LCA, unliganded opsin mole-
cules are in excess to chromophore molecules. Then the available
chromophore would effectively limit detection of light, and visual
function would be lost only when degeneration reduces the number
of opsin molecules to be equal or less than the chromophore
molecules available. A second hypothesis is that the chromophore
production increases with progression of RPE65 disease and as-
sociated accumulation of retinyl esters within the RPE. This hy-
pothesis has been raised to explain an age-related increase in
sensitivity observed in Rpe65−/− mice (21). An increase in chro-
mophore production could partially compensate for the loss of
photoreceptors by increasing the proportion of regenerated opsin
molecules in remaining cells. A third hypothesis would involve
cones as the basis of stable visual function and the majority of rods
showing the progressive degeneration. All three of these hypoth-
eses could possibly explain the results in untreated eyes with ∼5 log
units loss of light sensitivity but are unlikely to explain the obser-
vations in the treated eyes, where (rod-mediated) sensitivities can
Fig. 5. Histologic evaluation of the RPE65-mutant dog D23 treated at 0.3 y before the onset of retinal degeneration shows remarkable rescue of photo-
receptors from degeneration when assessed over a decade later. (A) Schematic representation of the en face image showing the treatment area (dashed
lines), on which is superimposed the ONL rows (mean of three values in area sampled) and disease staging (a, advanced atrophy with gliosis and loss of retinal
layer organization; m, moderate photoreceptor loss with 1/3 to 1/2 of ONL remaining; n, normal) assessed at 11.2 y. (B–D) Representative photomicrographs
taken from areas identiﬁed in A. In the treatment area, there is normal retinal preservation (B), although the RPE shows vacuolated inclusions typical of the
disease (arrowheads). At the edge of the treatment border (C), the photoreceptor layer becomes markedly attenuated and is absent (D) outside of the
treatment region. (B1, C1, and D1) Double immunolabeling with RPE65 (red) and rod opsin (green) taken from regions corresponding to B–D. Labeling in RPE
is present inside the treatment region (B), with some cells intensely labeled and others (vertical arrows) showing weaker immunolabeling. In the transition
zone (C1), RPE65 labeling is absent, and opsin labeling reﬂects rod OS shortening and disorientation; outside the treatment area (D1), the photoreceptor layer
is absent, and the inner nuclear layer (INL) is disorganized. (E and F) Control sections from WT dog (E) and RPE65-mutant dog in early stages of degeneration
(F) show, respectively, the presence (red) or absence of speciﬁc RPE65 immunolabeling in the RPE. GCL, ganglion cell layer; NFL, nerve ﬁber layer; OPL, outer
plexiform layer; OS/IS, outer and inner segment layer; INL, inner nuclear layer; IPL, inner plexiform layer. (Calibration: 20 μm.)














approach within 1 log unit of normal. A fourth hypothesis, more
consistent with our data, is that RPE65-LCA photoreceptors show
a spectrum of preapoptotic cellular stress states. At one end of the
spectrum are functionally silent cells that are next in line to be lost
to degeneration, and at the other end are healthier and functionally
potent cells that will survive the longest. In this case, degeneration
would progress with a constant rate of exponential decay after the
disease onset (25, 26, 39–41). Initially, there would be little loss of
function, but later, vision would be affected more and more at the
late-disease stages with RPE atrophy, when there is loss of a critical
number of last-remaining functionally potent (rod and cone)
photoreceptors. Preliminary evidence for such a progression is
observed as falling off a “cliff” of visual function near the periph-
eral boundaries of the visual ﬁeld (27).
Gene augmentation therapy in RPE65-mutant patients, mice,
and dogs has shown relative safety and remarkable improvement
in visual function (11, 16, 35). Future human studies are being
proposed to continue and expand the same therapeutic strategy.
However, there is mounting evidence for a need to reﬁne the
initial approaches. One need for reﬁnement is to understand
sufﬁciently the visual cycle of human foveal cones to make the
treatment efﬁcacious for visual acuity (11). Another need, re-
vealed in the present study, would be to seek a more complete
therapeutic outcome that involves both visual improvement and
structural rescue in extrafoveal retinal regions. The latter di-
rection can be determined experimentally in older Rpe65-mutant
mice and dogs that show both dysfunction and degeneration
phases of the disease. In other words, there is a need to advance
the therapy by taking a step back to proof-of-concept studies in
animals at ages that better model the human patients. Among the
possibilities to consider for reﬁnement is delivery of agents to pre-
vent the loss of retinal cells, such as neuroprotective, prosurvival,
or antiapoptotic factors or antioxidants (66–69), sequentially or
simultaneously with a more advanced version of gene augmenta-
tion therapy to increase chromophore to the remaining rod, ex-
trafoveal cone, and foveal cone photoreceptors.
Materials and Methods
Human Subjects. Patients (n = 23) with RPE65-LCA were included (Tables
S1 and S2). Informed consent was obtained. Procedures followed the Dec-
laration of Helsinki guidelines and were approved by the institutional review
board. Fifteen of the patients were enrolled in the clinical trial (NCT00481546).
Methodological details are provided in SI Materials and Methods.
Dogs. RPE65-mutant (n = 16) and normal (n = 11) dogs were included (Table
S3). All procedures involving animals (34, 35, 48, 65, 70) were performed in
compliance with the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision Research and
had Institutional Animal Care and Use Committee approval. Methodological
details are provided in SI Materials and Methods.
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